CLDX
Celldex Therapeutics Inc.
$30.85
+$0.12(+0.39%)
51
Overall
55
Value
60
Tech
39
Quality
Market Cap
$1.79B
Volume
726.20K
52W Range
$18.47 - $35.79
Target Price
$58.43
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M | ||
| Total Revenue | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-1.6M | $-700.0K | $-700.0K | $100.0K | $200.0K | $100.0K | $100.0K | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $139.7M | $122.1M | $85.9M | $58.1M | $57.0M | $73.8M | $109.5M | $148.9M | $202.1M | $288.9M | ||
| Research & Development | $102.7M | $96.2M | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | $245.1M | ||
| Research Expense | $102.7M | $96.2M | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | $245.1M | ||
| Selling, General & Administrative | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | $43.8M | ||
| General & Administrative Expenses | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | $43.8M | ||
| Salaries & Wages | -- | -- | -- | $-4.6M | $-3.9M | $-9.0M | $15.6M | -- | -- | -- | ||
| Depreciation & Amortization | $997.0K | $896.0K | $224.0K | $4.9M | $3.9M | $3.1M | $2.9M | $3.0M | $3.2M | -- | ||
| Depreciation & Amortization | $997.0K | $896.0K | $224.0K | $4.9M | $3.9M | $3.1M | $2.9M | -- | -- | -- | ||
| Amortization | $997.0K | $896.0K | $224.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | $-4.0M | $2.5M | $2.3M | $1.9M | $1.9M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-132.9M | $-109.3M | $-76.4M | $-55.0M | $-63.4M | $-71.2M | $-115.2M | $-154.5M | $-195.1M | $-287.4M | ||
| EBITDA | $-121.9M | $-112.3M | $-149.2M | $-47.2M | $-45.6M | $-66.1M | $-126.9M | $-152.1M | $-170.1M | $-255.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $4.4M | $4.2M | $4.5M | $4.2M | $2.4M | $505.0K | $2.9M | $13.1M | $37.2M | $28.6M | ||
| Net Non-Operating Interest Income/Expense | $4.4M | $4.2M | $4.5M | $4.2M | $2.4M | $505.0K | $2.9M | $13.1M | $37.2M | $28.6M | ||
| Other Income/Expense | $-2.8M | $-800.0K | $-10.9M | $506.0K | $13.8M | $2.1M | $-5.2M | $613.0K | $-3.1M | -- | ||
| Other Special Charges | -- | -- | $1.9M | $1.4M | $200.0K | $3.4M | $400.0K | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | $-13.0M | $-91.0M | -- | -- | -- | $-15.0M | $-12.5M | -- | -- | ||
| Impairment of Capital Assets | -- | $13.0M | $91.0M | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-128.5M | $-117.3M | $-151.9M | $-50.9M | $-49.6M | $-69.1M | $-129.8M | $-155.1M | $-173.2M | $-258.5M | ||
| Pre-Tax Income | $-128.5M | $-117.3M | $-151.9M | $-50.9M | $-60.9M | $-70.7M | $-112.3M | $-141.4M | $-157.9M | $-258.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-2.1M | $-24.3M | $-765.0K | $-13.9M | $-1.2M | $-227.0K | $-17.5M | $-13.7M | $-15.4M | $294.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | $-258.8M | ||
| Net Income (Continuing Operations) | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | $-258.8M | ||
| Net Income (Discontinued Operations) | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | $-258.8M | ||
| Net Income (Common Stockholders) | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | $-258.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-256.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $138.1M | $121.4M | $85.2M | $58.2M | $57.2M | $73.9M | $109.6M | $148.9M | $202.1M | $288.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $6.8M | $8.6M | $10.4M | $14.5M | $29.6K | $42.9K | $46.9K | $48.4K | $64.4K | $66.4M | ||
| Average Shares Outstanding (Diluted) | $6.8M | $8.6M | $10.4M | $14.5M | $29.6K | $42.9K | $46.9K | $48.4K | $64.4K | $66.4M | ||
| Shares Outstanding | $8.2M | $9.4M | $12.4M | $17.6M | $39.6M | $46.7M | $47.2M | $55.9M | $66.4M | $66.6M | ||
| Basic EPS | $-19.05 | $-10.8 | $-14.48 | -- | -- | $-1.64 | $-2.4 | $-2.92 | $-2.45 | $-3.9 | ||
| Basic EPS (Continuing Operations) | $-19.05 | $-10.8 | $-14.48 | -- | -- | -- | $-2.4 | $-2.92 | $-2.45 | $-3.9 | ||
| Diluted EPS | $-19.05 | $-10.8 | $-14.48 | $-3.51 | $-2.02 | $-1.64 | $-2.4 | $-2.92 | $-2.45 | $-3.9 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-3.51 | $-2.02 | -- | $-2.4 | $-2.92 | $-2.45 | $-3.9 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | $-700.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $2.8M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | $15.0M | $12.5M | -- | -- | ||
| Other Gand A | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | $43.8M | ||
| Other Impairment Of Capital Assets | -- | $-13.0M | $18.7M | $1.8M | $18.0M | $3.5M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-4.8M | $-4.1M | -- | -- | -- | $20.5M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLDX | $30.85 | +0.4% | 726.20K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Celldex Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW